89 results on '"Tasset, C."'
Search Results
2. DOP075 Efficacy of filgotinib, a selective JAK1 inhibitor, is independent of prior anti-TNF exposure: subgroup analysis of the phase 2 FITZROY study in moderate-to-severe Crohnʼs disease
3. OP023 Maintenance of clinical effect in patients with moderate-to-severe Crohnʼs disease treated with filgotinib, a selective JAK1 inhibitor: exploratory 20-week data analysis of the phase 2 FITZROY study
4. OP033 Reduction of tissue pSTAT3 in Crohnʼs disease patients treated with filgotinib (GLPG0634, GS-6034), a JAK1-selective inhibitor
5. Efficacy and Safety of Filgotinib as Maintenance Therapy for Patients with Moderately to Severely Active Ulcerative Colitis: Results from the Phase 2b/3 SELECTION Study
6. Efficacy and Safety of Filgotinib as Induction Therapy for Patients with Moderately to Severely Active Ulcerative Colitis: Results from the Phase 2b/3 SELECTION Study
7. OP0141 EFFECTS OF FILGOTINIB ON SPINAL LESIONS IN ANKYLOSING SPONDYLITIS: MAGNETIC RESONANCE IMAGING DATA FROM THE TORTUGA TRIAL
8. A15 EFFICACY AND SAFETY OF FILGOTINIB AS INDUCTION THERAPY FOR PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: RESULTS FROM THE PHASE 2B/3 SELECTION STUDY
9. A17 EFFICACY AND SAFETY OF FILGOTINIB AS MAINTENANCE THERAPY FOR PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: RESULTS FROM THE PHASE 2B/3 SELECTION STUDY
10. Efficacité à long terme du filgotinib (FIL) dans le traitement du rhumatisme psoriasique : résultats à S52 de l’étude d’extension en ouvert EQUATOR2
11. Effets à long terme sur le profil lipidique du filgotinib (FIL), inhibiteur spécifique de JAK1, dans le traitement du rhumatisme psoriasique : analyse des essais EQUATOR et EQUATOR2
12. Impact du filgotinib sur les lésions structurelles des articulations sacro-iliaques (ASI) à 12 semaines chez les patients atteints de spondylarthrite axiale (AxSpA) active : données d’Imagerie par résonance magnétique (IRM) issues de l’essai TORTUGA
13. Efficacité et tolérance du filgotinib chez les patients atteints de polyarthrite rhumatoïde (PR) présentant une réponse inadéquate au méthotrexate (RI-MTX) : résultats de l’étude FINCH 1 à 52 semaines
14. THU0198 EFFICACY AND SAFETY OF FILGOTINIB FOR PATIENTS WITH RHEUMATOID ARTHRITIS WITH INADEQUATE RESPONSE TO METHOTREXATE: FINCH 1 52-WEEK RESULTS
15. FRI0344 THE LONG-TERM EFFECT OF TREATING PSORIATIC ARTHRITIS WITH THE JANUS KINASE 1-SELECTIVE INHIBITOR FILGOTINIB ON LIPID PROFILES: AN ANALYSIS OF THE EQUATOR AND EQUATOR2 TRIALS
16. SAT0158 EFFICACY AND SAFETY OF FILGOTINIB IN METHOTREXATE-NAÏVE PATIENTS WITH RHEUMATOID ARTHRITIS: FINCH 3 52-WEEK RESULTS
17. THU0377 IMPACT OF FILGOTINIB ON STRUCTURAL LESIONS IN THE SACROILIAC JOINTS AT 12 WEEKS IN PATIENTS WITH ACTIVE AXIAL SPONDYLOARTHRITIS: MAGNETIC RESONANCE IMAGING DATA FROM THE DOUBLE-BLIND, RANDOMIZED TORTUGA TRIAL
18. FRI0343 EFFICACY AND SAFETY OF FILGOTINIB, A SELECTIVE JANUS KINASE 1 INHIBITOR, IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS: SUBGROUP ANALYSES FROM A RANDOMIZED, PLACEBO-CONTROLLED, PHASE 2 TRIAL (EQUATOR)
19. FRI0339 LONG-TERM EFFICACY OF THE ORAL SELECTIVE JANUS KINASE 1 INHIBITOR FILGOTINIB IN PSORIATIC ARTHRITIS: WEEK 52 RESPONSE PATTERNS IN INDIVIDUAL PATIENTS FROM AN OPEN-LABEL EXTENSION (OLE) STUDY (EQUATOR2)
20. P418 Filgotinib decreases molecular markers of JAK1 signal transduction in Crohn’s disease: concordance with endoscopy and histopathology
21. P372 Effects of filgotinib on anaemia, thrombocytopenia and leukopenia: Phase 3 study results in patients with active rheumatoid arthritis and prior inadequate response/intolerance to biological DMARDs
22. P597 Pooled safety analyses from Phase 3 studies of filgotinib in patients with rheumatoid arthritis
23. Filgotinib, an oral JAK1 selective inhibitor with a rapid onset of action: results from the DARWIN 1 study in methotrexate inadequate response rheumatoid arthritis patients
24. Filgotinib, ein oraler, selektiver Januskinase-1-Inhibitor ist bei Patienten mit aktiver ankylosierender Spondylitis und unzureichendem Ansprechen auf NSAR wirksam: Ergebnisse aus einer randomisierten, placebokontrollierten Phase-II-Studie
25. Post hoc Analyse der Phase 2 FITZROY Studie mit Filgotinib, einem selektiven JAK1 Inhibitor: Einfluss der Krankheitsdauer und -lokalisation auf die klinische Remission in Patienten mit Morbus Crohn
26. SAT0231 Effects of the jak1-selective inhibitor filgotinib on gene expression profile in blood of patients with active rheumatoid arthritis
27. PTU-003 Filgotinib decreases inflammatory markers associated with endoscopic improvement in moderate to severely active crohn’s disease
28. P643 Filgotinib decreases systemic and mucosal markers of inflammation that are associated with endoscopic improvement in moderately to severely active Crohn’s disease patients
29. P633 Concordance between endoscopy and histology scores at baseline and following induction therapy with the JAK1 inhibitor filgotinib in active Crohn’s disease: Results from FITZROY study
30. Mycobactéries atypiques dans la mucoviscidose à La Réunion
31. Filgotinib, an oral JAK1 selective inhibitor, is effective in combination with methotrexate and as monotherapy in patients with active rheumatoid arthritis: results from two Phase 2B studies (DARWIN 1 and DARWIN 2)
32. Filgotinib, ein selektiver JAK1-Inhibitor, induziert klinische Remission und Senkung der pSTAT3-Werte in Patienten mit aktivem Morbus Crohn: Ergebnisse der Phase 2 FITZROY Studie
33. THU0182 Monotherapy with the jak1-selective inhibitor filgotinib displays an anti-inflammatory biomarker profile in rheumatoid arthritis patients
34. THU0205 Effects of the jak1-selective inhibitor filgotinib on multibiomarker disease activity scores in patients with active rheumatoid arthritis and an inadequate response to methotrexate
35. THU0173 Long term safety and efficacy of filgotinib in a phase 2B open label extension study in patients with rheumatoid arthritis: results up to 144 weeks
36. OP0229 Effect of baseline serum crp levels on clinical efficacy in rheumatoid arthritis patients treated with filgotinib: post-hoc analysis from two phase 2b studies
37. THU0206 The jak1-selective inhibitor filgotinib reduces multiple markers of inflammation linked to various pathologic cell types and processes in rheumatoid arthritis patients
38. DOP075 Efficacy of filgotinib, a selective JAK1 inhibitor, is independent of prior anti-TNF exposure: subgroup analysis of the phase 2 FITZROY study in moderate-to-severe Crohn's disease
39. Filgotinib (GLPG0634/GS-6034), an oral JAK1 selective inhibitor, is effective in combination with methotrexate (MTX) in patients with active rheumatoid arthritis and insufficient response to MTX: results from a randomised, dose-finding study (DARWIN 1)
40. Filgotinib (GLPG0634/GS-6034), an oral selective JAK1 inhibitor, is effective as monotherapy in patients with active rheumatoid arthritis: results from a randomised, dose-finding study (DARWIN 2)
41. THU0173 Filgotinib (GLPG0634), An Oral Jak1 Selective Inhibitor Is Effective as Monotherapy in Patients with Active Rheumatoid Arthritis: Results from A 24-Week Phase 2B Dose Ranging Study: Table 1.
42. OP0224 Filgotinib (GLPG0634), An Oral Jak1 Selective Inhibitor Is Effective in Combination with Methotrexate in Patients with Active Rheumatoid Arthritis: Results from A 24-Week Phase 2B Dose Ranging Study: Table 1.
43. THU0167 The Effect of Filgotinib (GLPG0634), An Oral Jak1 Selective Inhibitor on Patient-Reported Outcomes: Results from Two 24-Week Phase 2b Dose Ranging Studies: Table 1.
44. AB0494 Filgotinib (GLPG0634), a Selective JAK1 Inhibitor, Shows Similar PK and PD Profiles in Japanese and Caucasian Healthy Volunteers
45. Filgotinib (GLPG0634/GS-6034), an oral selective JAK1 inhibitor, is effective as monotherapy in patients with active rheumatoid arthritis: results from a randomised, dose-finding study (DARWIN 2).
46. Filgotinib (GLPG0634/GS-6034), an oral JAK1 selective inhibitor, is effective in combination with methotrexate (MTX) in patients with active rheumatoid arthritis and insufficient response to MTX: results from a randomised, dose-finding study (DARWIN 1).
47. OC-048 Filgotinib, a selective jak1 inhibitor, induces clinical remission and a reduction in pstat3 levels in patients with active crohn’s disease: results from the phase ii fitzroy study
48. Nonsense mutations accelerate lung disease and decrease survival of cystic fibrosis children.
49. Long-term safety and efficacy of filgotinib treatment for rheumatoid arthritis in Japanese patients naïve to MTX treatment (FINCH 3).
50. Safety and efficacy of filgotinib for Japanese patients with RA and inadequate response to MTX: FINCH 1 52-week results and FINCH 4 48-week results.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.